JP Morgan estimated that the effects of GLP-1 drug use could reduce annual food and beverage industry revenue by $30 billion to $55 billion by 2030
Germany's approach is likely to attract more investment in clinical trials, benefiting the entire European research ecosystem clinical trials bring substantial economic benefits, with a multi-billion Euro impact
Through activation of the GLP-1 receptor, it enhances insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces food intake via central appetite regulation
Archives of Internal Medicine Research, 8(1), 113
Superoxide dismutase activity as a predictor of adverse outcomes in patients with nonischemic dilated cardiomyopathy
Possible Effects on Addiction and Reward Pathways Researchers are actively studying GLP-1 medications for their possible role in reducing: Alcohol cravings Nicotine cravings Compulsive shopping Gambling urges Other dopamine-driven behaviors Some patients report reduced interest in alcohol or other compulsive behaviors while on treatment